CRISPR-Cas: a new tool to diagnose infectious diseases
Keywords:
genetic edition, diagnosis, detection, COVID-19, SARS-CoV-2Abstract
This article presents a new use of the CRISPR-Cas genomic editing technology, which allowed Jennifer Doudna and Emmanuelle Charpentier to win the 2020 Nobel Prize in Chemistry. This tool not only allows the modification of DNA sequences but can also be used as a very rapid and sensitive test for clinical diagnosis. Due to the recent pandemic, there has been an exponential growth in methods to detect SARS-CoV-2, among which CRISPR-Cas stands out. The use of this technology allowed us to create a rapid and inexpensive test that can be easily implemented to increase the number of tests performed and thus contribute to a better control of the pandemic. Its role in molecular diagnosis also has great potential not only for detecting the presence of viruses and bacteria but also to diagnose non-infectious diseases such as cancer.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Revista Digital Universitaria es editada por la Universidad Nacional Autónoma de México se distribuye bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional. Basada en una obra en http://revista.unam.mx/.